Search research articles
Contact Us
Filters
Showing results (151-160 of 237) with videos related to
Page
of 24
Sort By:
Biochemistry
|
November 3, 2004
Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability
Marianne S Poruchynsky, Jong-Hyeok Kim, Eva Nogales, et al.
Breast Cancer Research and Treatment
|
November 13, 2023
Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials
Celine Yeh, Mengxi Zhou, Neil Bapodra, et al.
Surgery
|
November 19, 2013
MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors
Dhaval Patel, Myriem Boufraqech, Meenu Jain, et al.
The Oncologist
|
October 8, 2008
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data
Wilfred D Stein, William Doug Figg, William Dahut, et al.
The Oncologist
|
May 11, 2025
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan
Philip He, Dhiraj Gambhire, Haiming Zhou, et al.
Biochemical Pharmacology
|
February 1, 2008
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))
Robert W Robey, Suneet Shukla, Elizabeth M Finley, et al.
The New England Journal of Medicine
|
August 31, 2012
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia
Zhengping Zhuang, Chunzhang Yang, Felipe Lorenzo, et al.
Cancer
|
April 1, 2005
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
Sen H Zhuang, Manish Agrawal, Maureen Edgerly, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 23, 2026
Early treatment outcome prediction in metastatic castration-resistant prostate cancer utilizing 3-month tumor growth rate ( <i>g</i> -rate) based machine learning model
Esther C Ugwueke, Mohamed Azzam, Mengxi Zhou, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 16, 2014
The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer
Ciara O'Sullivan, Maureen Edgerly, Margarita Velarde, et al.
Page
of 24
Search research articles
Search
Showing results (151-160 of 237) with videos related to
Sort By:
Page
of 24
Biochemistry
|
November 3, 2004
Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability
Marianne S Poruchynsky, Jong-Hyeok Kim, Eva Nogales, et al.
Breast Cancer Research and Treatment
|
November 13, 2023
Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials
Celine Yeh, Mengxi Zhou, Neil Bapodra, et al.
Surgery
|
November 19, 2013
MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors
Dhaval Patel, Myriem Boufraqech, Meenu Jain, et al.
The Oncologist
|
October 8, 2008
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data
Wilfred D Stein, William Doug Figg, William Dahut, et al.
The Oncologist
|
May 11, 2025
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan
Philip He, Dhiraj Gambhire, Haiming Zhou, et al.
Biochemical Pharmacology
|
February 1, 2008
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R))
Robert W Robey, Suneet Shukla, Elizabeth M Finley, et al.
The New England Journal of Medicine
|
August 31, 2012
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia
Zhengping Zhuang, Chunzhang Yang, Felipe Lorenzo, et al.
Cancer
|
April 1, 2005
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
Sen H Zhuang, Manish Agrawal, Maureen Edgerly, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 23, 2026
Early treatment outcome prediction in metastatic castration-resistant prostate cancer utilizing 3-month tumor growth rate ( <i>g</i> -rate) based machine learning model
Esther C Ugwueke, Mohamed Azzam, Mengxi Zhou, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 16, 2014
The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer
Ciara O'Sullivan, Maureen Edgerly, Margarita Velarde, et al.
Page
of 24